Loading...
XTAEBIOV
Market cap10mUSD
Dec 24, Last price  
29.60ILS
1D
1.72%
1Q
4.96%
Jan 2017
-99.99%
IPO
-100.00%
Name

Bio-View Ltd

Chart & Performance

D1W1MN
XTAE:BIOV chart
P/E
10,007.27
P/S
110.24
EPS
0.00
Div Yield, %
0.00%
Shrs. gr., 5y
58.23%
Rev. gr., 5y
6.58%
Revenues
35m
+19.29%
25,318,00026,169,00026,047,00023,026,00030,242,00034,534,00033,289,00027,760,00025,280,00035,790,00025,960,00030,513,00029,145,00034,767,000
Net income
383k
-34.75%
5,236,0006,576,0001,442,000-1,076,0002,108,0004,066,0004,437,000-1,252,000-1,854,0002,525,000884,0002,184,000587,000383,000
CFO
153k
-84.19%
3,276,0002,350,000-2,916,0003,277,0004,662,0003,727,00054,000-1,325,0002,496,000802,0003,247,000968,000153,000
Dividend
Mar 22, 20172 ILS/sh

Profile

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.
URL
http://bioview.com
IPO date
Mar 07, 2006
Employees
34
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
34,767
19.29%
29,145
-4.48%
30,513
17.54%
Cost of revenue
34,630
21,552
20,700
Unusual Expense (Income)
NOPBT
137
7,593
9,813
NOPBT Margin
0.39%
26.05%
32.16%
Operating Taxes
414
288
499
Tax Rate
302.19%
3.79%
5.09%
NOPAT
(277)
7,305
9,314
Net income
383
-34.75%
587
-73.12%
2,184
147.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,679)
(256)
BB yield
3.64%
0.00%
Debt
Debt current
1,555
1,265
1,081
Long-term debt
5,457
6,851
8,135
Deferred revenue
620
533
Other long-term liabilities
790
364
429
Net debt
(10,102)
(11,321)
(10,007)
Cash flow
Cash from operating activities
153
968
3,247
CAPEX
(274)
(457)
(659)
Cash from investing activities
(1,673)
(567)
(740)
Cash from financing activities
(2,683)
(1,612)
(268)
FCF
(1,124)
7,050
5,330
Balance
Cash
17,114
19,437
19,223
Long term investments
Excess cash
15,376
17,980
17,697
Stockholders' equity
(23,206)
(23,841)
(24,639)
Invested Capital
54,807
56,932
57,369
ROIC
12.78%
16.74%
ROCE
0.43%
22.95%
29.98%
EV
Common stock shares outstanding
140,119
13,908
13,976
Price
0.33
-99.99%
3,697.00
13.09%
3,269.00
-18.48%
Market cap
46,099
-99.91%
51,417,251
12.54%
45,687,613
-18.97%
EV
35,997
51,405,930
45,678,180
EBITDA
1,955
9,088
11,289
EV/EBITDA
18.41
5,656.46
4,046.26
Interest
311
236
232
Interest/NOPBT
227.01%
3.11%
2.36%